BMEZ: Removal Of Options Should Improve Performance (Rating Upgrade)
BMEZ offers exposure to healthcare innovation but faces NAV instability and dividend sustainability concerns. Read why the BMEZ CEF is upgraded to hold.
SeekingAlphaMay 28, 5:40 AM
AL
NEW YORK STOCK EXCHANGE, INC.
HQL
abrdn Life Sciences Investors
Updated Jun 3, 2026, 3:55 PM
Last price
$16.96
Day change
-$0.22 (-1.28%)
Open
$17.13
Day range
$16.92 - $17.13
Volume
-
News
Latest company headlines from the cached provider feed.
Updated Jun 3, 2026, 3:55 PM
abrdn Life Sciences Investors Q1 2026 Commentary
The equity portion of the Abrdn Life Sciences Investors Fund rose (gross of fees) but underperformed its benchmark, the NASDAQ Biotechnology Index. Read more here.
SeekingAlphaMay 20, 11:40 AM
HQL: Attractive Outlook With Growth Of GLP-1 Market
Discover why HQL earns a buy rating: 12.6% yield, 8.49% NAV discount, GLP-1 biotech upside, plus key risks for income investorsâread now.
SeekingAlphaMay 19, 8:31 AM